What is Sigyn Therapeutics Inc's earnings per share (EPS)?

Sigyn Therapeutics Inc (SIGY) reported diluted earnings per share of $-2.51 for fiscal year 2024. This represents a 33.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Sigyn Therapeutics Inc Financials

SIGY

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Sigyn Therapeutics Inc (SIGY) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SIGY FY2024 2026-04-22

External financing is sustaining a pre-revenue research effort as cash burn moderates but the balance sheet keeps thinning.

From FY2023 to FY2024, operating cash burn improved from -$1.38M to -$872K. But cash still ended at only $12K because financing inflows of $873K largely just replaced what operations consumed, so lower burn did not translate into stronger liquidity and new capital is still acting as the cash bridge.

R&D spending stayed near $773K in FY2024 versus $798K in FY2023, even as overall cash use eased. At the same time, total assets slipped from $322K to $214K, implying the research effort is being expensed as it goes rather than turning into a thicker operating asset base; the main output of spending is continued development, not balance-sheet buildup.

Liquidity pressure is unusually acute: current assets were just $21K against current liabilities of $4.6M, leaving almost no short-term cushion. With negative equity at -$4.5M and a current ratio of 0.0046, liabilities are effectively funding the entire balance sheet and more, which makes the company structurally dependent on creditors and ongoing capital raising rather than internally generated resources.

Financial Health Signals

Financial Profile 0/100

Based on FY2024 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Sigyn Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Sigyn Therapeutics Inc has elevated debt relative to equity (D/E of -0.45), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.

Liquidity

Sigyn Therapeutics Inc's current ratio of 0.00 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

$-2.51

YoY+33.4%

Sigyn Therapeutics Inc earned $-2.51 per diluted share (EPS) in fiscal year 2024. This represents an increase of 33.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$12K

YoY+3.9%

5Y CAGR+89.3%

Sigyn Therapeutics Inc held $12K in cash against $2.0M in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

YoY+24.6%

Sigyn Therapeutics Inc had 2M shares outstanding in fiscal year 2024. This represents an increase of 24.6% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$773K

YoY-3.1%

Sigyn Therapeutics Inc invested $773K in research and development in fiscal year 2024. This represents a decrease of 3.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

SIGY Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	N/A	$143K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	$36K
Gross Profit	N/A	N/A	N/A	N/A	N/A	$108K
R&D Expenses	$773K-3.1%	$798K+21.4%	$658K-10.4%	$734K+75.0%	$419K	N/A
SG&A Expenses	N/A	N/A	$1.5M+16.9%	$1.3M+156.7%	$496K-19.1%	$614K
Operating Income	N/A	N/A	N/A	-$2.0M-119.1%	-$916K-76.9%	-$518K
Interest Expense	N/A	N/A	N/A	$31K-91.0%	$343K+521.7%	$55K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	-$3.0M-138.5%	-$1.3M+59.0%	-$3.1M
EPS (Diluted)	$-2.51+33.4%	$-3.77-20.4%	$-3.13	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$30K+296.7%	$7K-15.4%	$9K	N/A	$206K-14.3%	$240K+3.4%	$233K	N/A
SG&A Expenses	$307K	N/A	$487K	N/A	$565K+73.8%	$325K-9.6%	$360K	N/A
Operating Income	-$387K	N/A	-$546K	N/A	-$808K-34.1%	-$603K+4.3%	-$630K	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$579K	N/A	-$669K	N/A	-$1.2M-38.8%	-$862K-13.8%	-$758K	N/A
EPS (Diluted)	$-0.36+60.0%	$-0.90-114.3%	$-0.42	N/A	$-0.94-34.3%	$-0.70-12.9%	$-0.62	N/A

SIGY Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$214K-33.6%	$322K-3.3%	$333K-53.1%	$710K+2.3%	$694K	$0
Current Assets	$21K-82.0%	$118K+67.9%	$70K-82.1%	$393K-41.4%	$670K+13.9%	$589K
Cash & Equivalents	$12K+3.9%	$12K+39.9%	$8K-97.5%	$341K+304.0%	$84K+16780.4%	$500
Inventory	N/A	$50K0.0%	$50K0.0%	$50K-91.5%	$586K-0.4%	$588K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$4.7M+25.1%	$3.7M+67.0%	$2.2M+129.4%	$975K+63.9%	$595K+65274.0%	$910
Current Liabilities	$4.6M+27.9%	$3.6M+76.1%	$2.0M+179.0%	$734K+23.4%	$595K+65274.0%	$910
Long-Term Debt	$2.0M-19.4%	$2.5M+10.0%	$2.3M	N/A	N/A	N/A
Total Equity	-$4.5M-30.6%	-$3.4M-79.3%	-$1.9M-619.3%	-$265K-366.8%	$99K+10998.8%	-$910
Retained Earnings	-$14.7M-29.5%	-$11.3M-57.6%	-$7.2M-68.7%	-$4.3M-238.2%	-$1.3M-81263.9%	-$2K

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$136K+161.9%	$52K-78.8%	$244K+14.3%	$214K-50.0%	$427K+33.5%	$320K-1.0%	$323K+0.5%	$322K
Current Assets	$86K+4764.8%	$2K-97.4%	$68K+220.5%	$21K-92.1%	$269K+83.8%	$146K+8.9%	$134K+13.9%	$118K
Cash & Equivalents	$86K+18542.9%	$459-96.4%	$13K+6.2%	$12K-92.6%	$165K+207.2%	$54K+63.4%	$33K+180.9%	$12K
Inventory	N/A	N/A	N/A	N/A	$50K0.0%	$50K0.0%	$50K0.0%	$50K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$6.1M+10.3%	$5.5M+5.8%	$5.2M+11.1%	$4.7M+7.4%	$4.4M+9.0%	$4.0M-8.1%	$4.3M+16.3%	$3.7M
Current Liabilities	$4.0M-27.3%	$5.5M+6.5%	$5.2M+11.6%	$4.6M+7.9%	$4.3M+9.6%	$3.9M-7.9%	$4.2M+17.4%	$3.6M
Long-Term Debt	$3.5M+42.6%	$2.5M+3.7%	$2.4M+18.8%	$2.0M+1.3%	$2.0M-0.7%	$2.0M-27.8%	$2.8M+11.0%	$2.5M
Total Equity	-$5.9M-8.8%	-$5.4M-10.0%	-$4.9M-10.9%	-$4.5M-13.6%	-$3.9M-6.8%	-$3.7M+8.7%	-$4.0M-17.8%	-$3.4M
Retained Earnings	-$17.4M-3.4%	-$16.8M-9.5%	-$15.4M-4.6%	-$14.7M-3.7%	-$14.2M-9.2%	-$13.0M-7.1%	-$12.1M-6.7%	-$11.3M

SIGY Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$872K+36.9%	-$1.4M	N/A	-$1.8M-113.8%	-$830K-477.5%	-$144K
Capital Expenditures	N/A	N/A	$860-97.1%	$29K	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	-$1.8M	N/A	N/A
Investing Cash Flow	N/A	N/A	-$860+97.1%	-$29K-171.0%	-$11K-110.8%	$100K
Financing Cash Flow	$873K-37.0%	$1.4M-7.5%	$1.5M-27.3%	$2.1M+122.7%	$925K+2421.4%	$37K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	-$199K-30.8%	-$152K+48.2%	-$294K-1.5%	-$290K-77.2%	-$164K+10.4%	-$183K+22.4%	-$236K-84.2%	-$128K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$284K+103.2%	$140K-52.6%	$295K+114.6%	$138K-50.0%	$275K+35.0%	$204K-20.7%	$257K+242.3%	$75K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SIGY Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	75.1%
Operating Margin	N/A	N/A	N/A	N/A	N/A	-361.4%
Net Margin	N/A	N/A	N/A	N/A	N/A	-2145.3%
Return on Equity	N/A	N/A	N/A	N/A	-1270.0%	N/A
Return on Assets	N/A	N/A	N/A	-423.0%-241.5pp	-181.5%	N/A
Current Ratio	0.00-0.0	0.030.0	0.03-0.5	0.54-0.6	1.13-645.7	646.82
Debt-to-Equity	-0.45+0.3	-0.73+0.5	-1.20+2.5	-3.68-9.7	6.00+7.0	-1.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-426.7%	N/A	-273.7%	N/A	-280.0%-10.7pp	-269.4%-34.9pp	-234.5%	N/A
Current Ratio	0.02+0.0	0.00-0.0	0.010.0	0.00-0.1	0.06+0.0	0.040.0	0.030.0	0.03
Debt-to-Equity	-0.60-0.1	-0.46+0.0	-0.49-0.0	-0.45+0.1	-0.51+0.0	-0.55+0.1	-0.69+0.0	-0.73
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$4.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

$3.5M

$4.6M

$13.9M

$6.8M

Pharmala Biotech MDXXF

$10.6M

Frequently Asked Questions

How much debt does Sigyn Therapeutics Inc have?

As of fiscal year 2024, Sigyn Therapeutics Inc (SIGY) had $12K in cash and equivalents against $2.0M in long-term debt.

What is Sigyn Therapeutics Inc's operating cash flow?

Sigyn Therapeutics Inc (SIGY) generated -$872K in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Sigyn Therapeutics Inc's total assets?

Sigyn Therapeutics Inc (SIGY) had $214K in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Sigyn Therapeutics Inc spend on research and development?

Sigyn Therapeutics Inc (SIGY) invested $773K in research and development during fiscal year 2024.

How many shares does Sigyn Therapeutics Inc have outstanding?

Sigyn Therapeutics Inc (SIGY) had 2M shares outstanding as of fiscal year 2024.

What is Sigyn Therapeutics Inc's current ratio?

Sigyn Therapeutics Inc (SIGY) had a current ratio of 0.00 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.

What is Sigyn Therapeutics Inc's debt-to-equity ratio?

Sigyn Therapeutics Inc (SIGY) had a debt-to-equity ratio of -0.45 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Sigyn Therapeutics Inc's cash runway?

Based on fiscal year 2024 data, Sigyn Therapeutics Inc (SIGY) had $12K in cash against an annual operating cash burn of $872K. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Sigyn Therapeutics Inc's debt-to-equity ratio negative or unusual?

Sigyn Therapeutics Inc (SIGY) has negative shareholder equity of -$4.5M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

How financially healthy is Sigyn Therapeutics Inc?

Sigyn Therapeutics Inc (SIGY) scores 0 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.